Related Experiment Videos

CYP3A5 polymorphism, amlodipine and hypertension

Y-P Zhang1, X-C Zuo2, Z-J Huang2

  • 11] Department of Cardiology, the Third Xiang-Ya Hospital, Central South University, Changsha, People's Republic of China [2] Center of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.

Journal of Human Hypertension
|July 19, 2013
PubMed

Insights

Hypertension, a major cardiovascular risk, may be linked to Cytochrome P450 3A5 (CYP3A5). This review explores CYP3A5

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenomics

Background:

  • Hypertension is a global health issue and cardiovascular risk factor.
  • Cytochrome P450 3A5 (CYP3A5) is implicated in blood pressure regulation and hypertension development.
  • CYP3A5 activity may influence renal sodium/water balance and response to antihypertensive drugs.

Purpose of the Study:

  • To review the current understanding of CYP3A5's role in hypertension.
  • To identify inconsistencies and limitations in existing research.
  • To guide future research directions in this field.

Main Methods:

  • Literature review of studies investigating CYP3A5 and hypertension.
  • Analysis of data on CYP3A5 genotypes and blood pressure response.
  • Synthesis of findings on CYP3A5's impact on hypertension development and treatment.

Main Results:

  • CYP3A5 may affect blood pressure through cortisol metabolism.
  • CYP3A5 genetic variations influence antihypertensive drug efficacy.
  • Current data on CYP3A5's role in hypertension is inconsistent.

Conclusions:

  • Further research is needed to clarify the complex relationship between CYP3A5 and hypertension.
  • Understanding CYP3A5's role could lead to personalized hypertension management.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...